GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Intrinsic Value: Projected FCF

CPMV (Mosaic ImmunoEngineering) Intrinsic Value: Projected FCF : $-1.97 (As of Jun. 16, 2025)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-16), Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF is $-1.97. The stock price of Mosaic ImmunoEngineering is $0.32856. Therefore, Mosaic ImmunoEngineering's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF or its related term are showing as below:

CPMV's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.16
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Mosaic ImmunoEngineering Intrinsic Value: Projected FCF Historical Data

The historical data trend for Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Intrinsic Value: Projected FCF Chart

Mosaic ImmunoEngineering Annual Data
Trend May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.14 -1.79 -2.21 -1.95 -1.97

Mosaic ImmunoEngineering Quarterly Data
May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.97 -2.00 -1.99 -1.97 -1.97

Competitive Comparison of Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Price-to-Projected-FCF falls into.


;
;

Mosaic ImmunoEngineering Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Mosaic ImmunoEngineering's Free Cash Flow(6 year avg) = $-0.58.

Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar25)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-0.58448+-6.969/0.8)/7.236
=-1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Mosaic ImmunoEngineering's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.32856/-1.9728724572705
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering Business Description

Traded in Other Exchanges
N/A
Address
9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering Headlines

From GuruFocus

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-15-2019